{
  "id": 21178928,
  "title": "What's Behind Grail Stock's Wild Ride in 2026, and What Can Investors Expect in 2027?",
  "url": "https://urgent.news/2026/11/22/whats-behind-grail-stocks-wild-ride-in-2026-and-what-can-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T06:07:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/22/what-s-behind-grail-stock-s-wild-ride-in-2026-and-what-can-investors-expect-in-2027/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Grail stock experienced significant fluctuations in 2026, and this pattern is expected to persist into 2027. The company's multi-cancer early detection (MCED) test, Galleri, is awaiting approval from the FDA, which is crucial for its future success. Despite disappointing top-line results from its large-scale three-year trial with England's National Health Service (NHS), Grail remains optimistic. The trial failed to meet its primary endpoint of detecting late-stage cancers more accurately, raising concerns about approval and insurance coverage. However, Grail's management is confident that the test's data are strong enough to convince the FDA and insurers of its value. This optimism was evident at the American Society of Clinical Oncology (ASCO) meeting in May, where Grail showcased data from both the NHS trial and a smaller trial involving 35,000 patients in the U.S. and Canada. Grail's stock soared in September after an FDA panel endorsed the test's safety and efficacy, setting the stage for FDA approval in 2027. The ultimate adoption of Galleri by insurers and medical bodies depends on various factors, including a cost-benefit analysis by insurers, which weigh the test's benefits against its cost and the potential for false positives. Additionally, Grail hopes Medicare will cover Galleri under the Nancy Sewell ACT, which would require a National Coverage Determination (NCD) from the Centers for Medicare & Medicaid Services (CMS). Ultimately, Grail's success hinges on insurers' willingness to pay for the test, with a projected price range of $500 to $600 per test. While there is still a long road ahead before Grail's future becomes clearer, the company's management is confident that FDA approval and subsequent discussions with commercial payers will pave the way for widespread adoption.",
  "summary": "The multi-cancer early detection test company's volatility is likely to continue next year.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "What's Behind Grail Stock's Wild Ride in 2026, and What Can Investors Expect in 2027?",
        "url": "https://urgent.news/2026/11/22/whats-behind-grail-stocks-wild-ride-in-2026-and-what-can-investors-21180355",
        "published": "2026-11-22T06:27:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}